GLP-1 Access and Transparency

Pairing high-quality, compounded medications with powerful lifestyle change is in the public interest.

GLP-1
Access and
Transparency

Pairing high-quality, compounded medications with powerful lifestyle
change is in the public interest.

Our CEO’s Statement

Our CMO’s Statement

Obesity is an epidemic.

7 in 10

have obesity or are overweight¹

5 in 10

are interested in weight loss drugs²

1 in 4

will be considered severely obese by 2030³

Brand-name meds are scarce and expensive in the United States.

It’s a fact that brand-name GLP-1 medications are cost-prohibitive and difficult to obtain. That’s why Noom offers both brand-name and compounded medications to give our customers more options to get the medications they need. Our mission is to empower everyone, everywhere to live better longer – not only those with great insurance.

$1,349

US list price of a popular GLP-1 medication⁴

$137

Price of the same drug in Germany⁵

$149

The starting price of Noom GLP-1^Rx

Safety is paramount.

Noom has partnered with a 503B, FDA-regulated outsourcing facility to manufacture and supply its compounded GLP-1s.* While the FDA has declared the medication in shortage, essential copies of the active ingredient may be compounded and distributed legally in the United States.

cGMP Regulations

503B facilities are held to a higher standard. They must comply with the FDA’s current Good Manufacturing Practices (cGMP) –  the same standards as the pharmaceutical companies manufacturing brand-name medications.

Fill Line Machine

The facility uses robotic, aseptic fill machines. The quality control process involves AI automated scanning for ingredients and contaminants, ensuring consistency and sterility.

Certificate of Analysis (COA)

Noom Med patients prescribed compounded medication may request a COA from their care coordination team (careteam@noom.com), providing utmost transparency as to the ingredients and quality of each batch of medication. A COA is a document provided by a 503B outsourcing facility showing that the medication meets regulatory requirements.

Our intake process:

We verify the identity of every patient.

We require a full-body photo before treatment.

We require a comprehensive medical intake.

We verify the identity of every patient.

We require a full-body photo before treatment.

We require a comprehensive medical intake.

Medication alone is not enough.

It says so right on the label: GLP-1s are to be used “in combination with a reduced calorie diet and increased physical activity.”

Without a companion program, it’s possible to end up with sarcopenic obesity and a higher body fat composition than before starting the meds—up to 40% of weight loss can be muscle.⁶

Behavior change combined with GLP-1s drives lasting weight loss.

Absent behavior change, most of the lost weight will come back within 12 months of stopping the med.

Behavior Change Group Maintains Weight Loss Better⁷

6 out of 7 people stop taking GLP-1s⁸.

The vast majority of people stop taking their GLP-1 meds by month 24. That’s why having a companion program is vital to maintaining weight loss success.

Powerful meds need a powerful companion.

Take a GLP-1 the right way, with Noom’s GLP-1 Companion with Muscle Defense^TM.

Keep the muscle, lose the fat

Develop healthy habits

Find support in community

Ask your 1:1 coach anything

Noom GLP-1^Rx Taper Off Guarantee

To those who wish to one day live med free, we offer the Noom GLP-1^Rx Taper Off Guarantee. If you regain the weight within 18 months following a 12-month course of Noom GLP-1^Rx, including the Noom Taper Protocol, as well as engage with our program by earning an average of 10 or more NoomCoin per month, then we’ll give you a year of free Noom or a substantial discount on future meds.

Learn More

Noom Science Advisory Board

Shawn Cole

Dr. Cole is double board-certified in internal medicine, having completed his training at Yale-New Haven Hospital, and in obesity medicine. He has extensive experience as a leader in academic primary care, telehealth, population health, and obesity medicine. He has a passion for combining evidence-based practice with innovative healthcare strategies that enable greater access to medical treatment for the optimization of chronic disease management. Holding Masters degrees in both Applied Nutrition and in Health Administration, Dr. Cole maintains a strong clinical leadership emphasis on utilizing an interprofessional, health technology-driven approach to improve outcomes in obesity.

Lindsey Connors

Lindsey Connors is a highly skilled pharmacist with a diverse focus including long-term care, compounding pharmacy, consulting, clinical research, and technical writing. She received specialized training in sterile compounding from Critical Point and has honed her skills through extensive experience in busy 503a compounding pharmacies. Lindsey has developed regulatory-compliant quality systems tailored for smaller pharmacies and has guided clients through the complexities of regulatory agencies such as the NABP, FDA, and various state boards of pharmacies. Her expertise extends to managing teams of professionals and support staff while overseeing the fiscal management of pharmacy operations. Known for her ability to build cohesive teams by balancing diverse perspectives and working towards shared objectives, Lindsey is licensed in Alabama, Florida, Illinois, Maryland, Michigan, Oklahoma, Texas, and Virginia.

Dr. Pouran Faghri

Dr. Pouran Faghri is an Adjunct Full Professor in the Department of Environmental Health Sciences at the Fielding School of Public Health, University of California, Los Angeles. As a pioneer in behavioral interventions for weight loss and maintenance, Dr. Faghri’s work includes the application of cognitive-behavioral techniques and social support to improve self-regulation, enhance self-efficacy, and increase self-control. She has also employed strategies from behavioral economics and contingency management for effective weight management. As an occupational health expert, Dr. Faghri’s comprehensive research portfolio encompasses the study of occupational health and safety, examining workplace stressors and their impact on chronic diseases such as mental health issues, cardiovascular conditions, obesity, and type 2 diabetes. A sought-after speaker at national and international conferences, she shares insights on public health advancements and strategies for promoting healthy living.

Andrew Gostine

Andrew Gostine, MD, MBA, is an accomplished healthcare professional passionate about leveraging artificial intelligence in the clinical setting. As a co-founder and the CEO of Artisight, he is at the forefront of fusing deep learning and IoT sensors to facilitate healthcare automation and optimization.

Dr. Gostine’s journey began as a critical care anesthesiologist, where he gained valuable insights into the evolving needs of practicing clinicians in the ICUs and operating rooms. This firsthand experience inspired him to establish Artisight with a vision to address real problems in hospital workflow to improve overall efficiencies.

Beyond his entrepreneurial pursuits, Dr. Gostine remains actively engaged in clinical practice. This dedication allows him to stay up-to-date with clinicians’ changing and dynamic needs, bridging the gap between technological advancements and their practical applications in healthcare.